Literature DB >> 23421425

Perinatal outcomes in oocyte donor pregnancies.

Andrea L Tranquilli1, Valentina Biondini, Solmas Talebi Chahvar, Alessandra Corradetti, Daniela Tranquilli, Stefano Giannubilo.   

Abstract

OBJECTIVE: To assess the obstetric outcomes of pregnancy following intracytoplasmic sperm injection (ICSI) using donor oocytes.
METHODS: Twenty-six deliveries from oocyte donor ICSI (d-ICSI) were compared to the next two consecutive deliveries from homologous ICSI (h-ICSI group) (n = 52) and with the two consecutive deliveries from women older than 40 years (Advanced Maternal Age: AMA) (n = 52). We evaluated the occurrence of gestational hypertension (GH), preeclampsia (PE), fetal growth restriction (IUGR), gestational diabetes mellitus (GDM), preterm premature rupture of membranes (pPROM), preterm birth, placental anomalies, mode of delivery, hemorrhage, gestational age at birth and birth weight.
RESULTS: d-ICSI had significantly more PE (d-ICSI 19.2%, h-ICSI 0%, AMA 0%, p < 0.001); higher rates of IUGR than AMA pregnancies (d-ICSI 19.2%, AMA 3.8%, p < 0.025). Placental accretism was found only in the d-ICSI group (15.4%, p < 0.043). No postpartum bleeding was observed.
CONCLUSIONS: This is the first study that compares the obstetric outcomes of donor pregnancies to the outcomes of h-ICSI and AMA. Obstetricians who deal with pregnancies from oocyte donation need to be aware of the more severe obstetric outcomes, especially placenta accreta and preeclampsia. All women who conceive through oocyte donation should be counseled as early as the pre-conception period and referred to specific centers for high-risk pregnancies.

Entities:  

Mesh:

Year:  2013        PMID: 23421425     DOI: 10.3109/14767058.2013.777422

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  8 in total

1.  Twin pregnancy in a 51-year-old woman who underwent autologous cryopreservation at the age of 36 years: case report.

Authors:  Tomoki Kotera; Takashi Shibata; Hiroki Kato; Hirohiko Watanabe; Satoshi Nakago
Journal:  Reprod Med Biol       Date:  2016-01-05

2.  Is the risk of preeclampsia higher in donor oocyte pregnancies? A systematic review and meta-analysis.

Authors:  Juan Enrique Schwarze; Paula Borda; Pamela Vásquez; Carolina Ortega; Sonia Villa; Javier A Crosby; Ricardo Pommer
Journal:  JBRA Assist Reprod       Date:  2018-03-01

3.  Trends and outcomes for donor oocyte cycles in the United States, 2000-2010.

Authors:  Jennifer F Kawwass; Michael Monsour; Sara Crawford; Dmitry M Kissin; Donna R Session; Aniket D Kulkarni; Denise J Jamieson
Journal:  JAMA       Date:  2013-12-11       Impact factor: 56.272

4.  Placenta accreta following hysteroscopic myomectomy.

Authors:  Mie Tanaka; Shinya Matsuzaki; Satoko Matsuzaki; Aiko Kakigano; Keiichi Kumasawa; Yutaka Ueda; Masayuki Endo; Tadashi Kimura
Journal:  Clin Case Rep       Date:  2016-04-20

5.  Neonatal outcomes in pregnancies resulting from oocyte donation: a cohort study in Sweden.

Authors:  Evangelia Elenis; Gunilla Sydsjö; Alkistis Skalkidou; Claudia Lampic; Agneta Skoog Svanberg
Journal:  BMC Pediatr       Date:  2016-10-21       Impact factor: 2.125

6.  Comparison of Obstetric Outcomes of Pregnancies after Donor-Oocyte In vitro Fertilization and Self-Oocyte In vitro Fertilization: A Retrospective Cohort Study.

Authors:  Vikas Yadav; Priyanka Bakolia; Neena Malhotra; Reeta Mahey; Neeta Singh; Alka Kriplani
Journal:  J Hum Reprod Sci       Date:  2018 Oct-Dec

7.  Comparison of Obstetric Outcomes Between IVF cycles with Donor Oocyte and Spontaneous Conception Pregnancies: A Retrospective Cohort study.

Authors:  Yadav Vikas; Malhotra Neena; Mahey Reeta; Singh Neeta; Kriplani Alka
Journal:  J Reprod Infertil       Date:  2022 Apr-Jun

8.  Pregnancy Achieved Using Donor Eggs in Cancer Survivors with Treatment-Induced Ovarian Failure: Obstetric and Perinatal Outcome.

Authors:  Anna Marklund; Josefine Nasiell; Ann-Sofie Berger; Antonia Fagerberg; Kenny A Rodriguez-Wallberg
Journal:  J Womens Health (Larchmt)       Date:  2018-05-01       Impact factor: 2.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.